Citations

Clear

3942 citation(s) found for "To, Van".

Genome‐wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease
Hou, Xu , Fiesel, Fabienne C. , White, Launia J. , Quicksall, Zachary , Reddy, Joseph S. , Ross, Owen A. , Valentino, Rebecca R. , Ross, Owen A , Fiesel, Fabienne C , Hou, Xu , Heckman, Michael G. , Koga, Shunsuke , Soto‐Beasley, Alexandra I. , Watzlawik, Jens O. , Zhao, Jing , Johnson, Patrick W. , Brás, José , Guerreiro, Rita , Zhao, Na , Bu, Guojun , Dickson, Dennis W. , Springer, Wolfdieter

Mayo Clinic

Alzheimer's & Dementia | May 1, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70198 | PMID 40309932 Get It

AbstractINTRODUCTIONPhosphorylated ubiquitin (p‐S65‐Ub) is generated during PINK1‐PRKN mitophagy as a specific marker of mitochondrial damage. Despite the widespread deposition of p‐S65‐Ub in aged and diseased human brain, the genetic contribution to its accumulation remains unclear.METHODSTo identify novel mitophagy regulators, we performed a genome‐wide association study using p‐S65‐Ub level as a quantitative trait in 1012 autopsy‐confirmed Lewy body disease (LBD) samples.RESULTSWe identified a significant genome‐wide association with p‐S65‐Ub for rs429358 (apolipoprotein E ε4 [APOE4]) and a suggestive association for rs6480922 (ZMIZ1). APOE4 was associated with higher p‐S65‐Ub levels and greater neuropathological burden. Functional validation in mouse and human induced pluripotent stem cell (iPSC) models confirmed APOE4‐mediated mitophagy alterations. Intriguingly, ZMIZ1 rs6480922 was associated with lower p‐S65‐Ub levels, reduced neuropathological load, and increased brain weight, indicating a potential protective role.DISCUSSIONOur findings underscore the importance of mitochondrial quality control in LBD pathogenesis and nominate regulators that may contribute to disease risk or resilience.Highlights p‐S65‐Ub levels were used as a quantitative marker of mitochondrial damage. A GWAS identified two genetic variants that modify mitophagy in LBD autopsy brain. APOE4 was associated with increased p‐S65‐Ub accumulation and neuropathology. APOE4 altered mitophagy via pathology‐dependent and pathology‐independent mechanisms. ZMIZ1 was linked to reduced p‐S65‐Ub and neuropathology indicative of protection.
Stress Echo 2030 Study: A Flagship Project of the Italian Society of Echocardiography and Cardiovascular Imaging
Picano, Eugenio, Padang, Ratnasari , Kane, Garvan C. , Villarraga, Hector R. , Arruda‐Olson, Adelaide M. , Vazquez, Jesus Peteiro , Boshchenko, A , Журавлева, О. А. , Sviazova, Natalia , Balkevičienė, Laura, Djordjevic‐Dikic, Ana , Kobal, Sergio , Lisi, Matteo , Merli, Elisa , Manganelli, F, Daros, Clarissa Borguezan , D’Alfonso, Maria Grazia , Mori, Fabio , Kasprzak, Jarosław D. , Safarova, Ayten, Timofeeva, T. N. , Mosto, Hugo , Wierzbowska‐Drabik, Karina , Ratanasit, Nithima , Colonna, Paolo , Ostojić, Miodrag , Cortigiani, Lauro , Rigo, Fausto , Benfari, Giovanni , Soulis, Dimitrios , Yin, Lixue , Mazzi, Alberto, Haber, Diego M. Lowenstein, Marconi, Sofia, Tripepi, Giovanni Luigi, Nes, Michele De, Bartolacelli, Ylenia , Villari, Bruno, Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Benfari, Giovanni , Colonna, Paolo , Boshchenko, Alla , Ciampi, Quirino , Arbucci, Rosina , Zagatina, A , Kalinina, Elena , Ryabova, Tamara , Čelutkienė, Jelena , Saad, Ariel K. , Bursi, Francesca , Rodríguez‐Zanella, Hugo , Gaibazzi, Nicola , Costantino, Marco Fabio , Kovačević-Preradović, Tamara , Varga, Albert , Nikolic, Aleksandra, Cocchia, Rosangela , Pálinkás, Attila , Pálinkás, Eszter Dalma , Valente, Filipa Xavier , Wang, Yi , Heyning, Caroline M. Van De , Mazzi, Alberto, Lowenstein, Jorge , Barbieri, Andréa , Mantovani, Francesca , Pepi, Mauro , Carerj, Scipione , Pellikka, Patricia A.

Mayo Clinic

Journal of Cardiovascular Echography | May 1, 2025 | Volume: 35 | Issue: 1 | Pages: 1-7

10.4103/jcecho.jcecho_2_25 | PMID 40463758 Get It

Over the past decade, stress echocardiography has evolved from a test for assessing epicardial artery stenosis to a comprehensive functional test, targeting multiple cardiovascular parameters. The new approach includes several structured steps: (a) evaluating regional wall motion abnormalities to detect epicardial artery stenosis or vasospasm; (b) assessing pulmonary congestion and diastolic function via B-lines with lung ultrasound; (c) gauging preload and contractile reserve with volumetric echocardiography; (d) measuring coronary microvascular reserve using Doppler-based coronary flow velocity in the middistal left anterior descending artery; and (e) determining cardiac sympathetic reserve by tracking heart rate reserve on an ECG. This evolution was supported extensively by the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI), which played a key role in five areas: (1) developing the initial, curiosity-driven project; (2) disseminating protocols and results at national and international conferences, supporting logistic infrastructure and publication expenses; (3) establishing a digital platform (customized Redcap) for data entry and storage; (4) facilitating patient recruitment across 19 Italian centers; and (5) offering formal endorsement through six presidencies, adding credibility and reach beyond any single institution. The protocol quickly advanced from concept to high-impact publications, earning inclusion in 2024 specialty guidelines. Initially Italian-led, the study now includes 50 centers across 20 countries (e.g. USA and China). Beyond the 50 peer-reviewed papers published in 2016–2024, this study offers a novel, sustainable approach to cardiac stress testing, providing more information at lower costs, with zero radiation and minimal environmental impact. SIECVI’s endorsement was instrumental in amplifying the study’s rigor and outreach.
Effect of very preterm delivery on outcomes following in utero spina bifida repair
Zaretsky, Michael V. , Anadkat, Jagruti , Bennett, Kelly, Blumenfeld, Yair J. , Buchanan, Christina , Clifford, Caitlin , Crombleholme, Timothy M., Emery, Stephen P. , Goodnight, William , Lee, Hanmin , Lillegard, Joseph B. , Luks, François I. , Moldenhauer, Julie S. , Schenone, Mauro , Skupski, Daniel, Wagner, Amy J., Elbabaa, Samer K. , Lim, Foong‐Yen Y. , Lijewski, Virginia A. , Miller, Jena L. , Moehrlen, Ueli , Moon‐Grady, Anita J. , Schenone, Mauro H , Shaaban, Aimen F. , Tsao, KuoJen , Van Mieghem, Tim

Mayo Clinic

Pregnancy | April 30, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1002/pmf2.70027 | PMID 40963542 Get It

Abstract Objective In utero fetal spina bifida repair decreases the risk for cerebrospinal fluid (CSF) diversion including ventriculoperitoneal (VP) shunt placement, reverses hindbrain herniation, and improves motor function with a higher likelihood of independent ambulation. Unfortunately, in utero surgery can be complicated by preterm delivery. The goal of this study was to compare pregnancy and neonatal outcomes between individuals who delivered very preterm, and those who delivered later in gestation following in utero spina bifida repair. Methods Data from the North American Fetal Therapy Network Fetal Myelomeningocele Consortium Registry collected from 2011 to 2024 were analyzed. Three cohorts of patients were categorized by gestational age at delivery and compared: <30 weeks, 30–34 weeks, and >34 weeks. Comparisons between groups for maternal and delivery outcomes were completed for the entire cohort and then analyzed for those with available CSF diversion data up to 1 year of life. Chi‐square or Fisher's exact tests were used to compare categorical variables, and Kruskal–Wallis tests were used to determine if there are significant differences between the distributions of the three groups. A p ‐value <0.05 was considered significant. Results A total of 1213 patients were analyzed (<30 weeks, n = 111 [9.2%]; 30–34 weeks, n = 323 [26.6%]; >34 weeks, n = 779 [64.2%]). Overall fetal and neonatal mortality was 2.2%, 85% of which occurred in the <30‐week cohort, where perinatal mortality was 21%. Latency from fetal surgery to delivery averaged 2.1 weeks for the <30‐week group. Rates of abruption, chorioamnionitis, and spontaneous labor were higher in the <30‐week group compared to later gestational age cohorts. Neonatal morbidity was also significantly higher in the <30‐week cohort for sepsis, apnea, respiratory distress, patent ductus arteriosus, intraventricular hemorrhage, and periventricular leukomalacia in the <30‐week cohort. CSF diversion data were available for 677 neonates (<30 weeks, n = 53; 30–34 weeks, n = 186; >34 weeks, n = 438). There was no significant difference in VP shunt placement between the different gestational age groups. Conclusion Very preterm birth following in utero spina bifida repair results in significant perinatal mortality and neonatal morbidity. Delivery prior to 30 weeks of gestation occurs in 9% of patients after in utero spina bifida repair, resulting in a 21% perinatal mortality rate. However, even among those who delivered very preterm, a reduction in VP shunt rates, a benefit of in utero repair, appears to be preserved. Further data are warranted to assess the impact of prematurity following in utero surgery on ambulation and developmental outcomes.
Rethinking the Diagnosis and Management of Antibody‐Mediated Rejection in Multidisciplinary Transplant Meetings: A Global Survey and Banff Working Group Recommendations
Sapir‐Pichhadze, Ruth , Cornell, Lynn D. , Dadhania, Darshana M. , Vries, Aiko P. J. de , Schinstock, Carrie A. , Carroll, Robert , Abdelrehim, Ahmad, Gan, Geliang, Deng, Yanhong , Alasfar, Sami , Bagnasco, Serena M. , Groningen, Marian C. Clahsen‐van , Kung, Vanderlene L. , Lower, Fritz, Seija, Mariana , Kraus, Edward S., Bow, Laurine M., Group, the Banff Antibody‐Mediated Injury Working, Dadhania, Darshana M , Schinstock, Carrie , Carroll, Robert P , Clahsen-van Groningen, Marian C , Cornell, Lynn , de Vries, Aiko P J , Askar, Medhat , Cooper, Matthew , Cozzi, Emanuele , Diekmann, Fritz , Gan, Geliang, Batal, Ibrahim , Budde, Klemens , Naesens, Maarten , Group, the Banff Antibody‐Mediated Injury Working

Mayo Clinic

Clinical Transplantation | April 28, 2025 | Volume: 39 | Issue: 5 | Pages: No page available

10.1111/ctr.70167 | PMID 40294134 Get It

ABSTRACTIntroductionThe diagnosis of antibody‐mediated rejection (AMR) requires input from several transplant professionals. Bringing clinical and laboratory experts together may help standardize care. Yet, little is known about current global practices of multidisciplinary meetings for AMR management.MethodsThe Banff Antibody‐Mediated Injury Working Group approached professional societies worldwide to distribute a survey on the availability, content, participants, perceived value, and barriers to the implementation of multidisciplinary meetings.ResultsFour hundred two transplant professionals from six continents caring for kidney (90.55%), liver (21.14%), pancreas (20.65%), heart (15.17%), and lung (14.18%) transplant recipients participated in the survey, and 302 (75.12%) reported attending multidisciplinary meetings. Multidisciplinary meetings were more prevalent in academic centers, in high‐ versus low‐to‐middle‐income regions (81.03% and 65.99%, respectively; p < 0.001), and in mid‐to‐large size transplant programs compared to smaller programs. Perceived value included continued professional development (97.68%) and trainee education (95.70%). AMR was reported to be discussed at these meetings by 217 respondents with case presentations reviewing patient characteristics, histology, and HLA antibody data. A third of the respondents reviewed non‐HLA/pathogenic autoantibodies and/or molecular diagnostics, with the latter being more frequently applied in high‐ versus low‐to‐middle‐income regions (46.71% and 12.31%, respectively; p < 0.001). AMR case presentations allowed diagnosis revision, actionable management plans and were perceived as improving care. The primary barrier to the implementation of multidisciplinary meetings (63.27%) was the unavailability of transplant professionals (e.g., transplant immunologists).ConclusionFacilitating multidisciplinary meetings through the remote participation of pertinent experts and incentivizing participation through remuneration, protected time, or continued medical education may help standardize AMR diagnosis and harmonize its management.
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative
Asogwa, Ogechukwu A , Walbert, Tobias , Arons, David, Blakeley, Jaishri O. , Coomans, Marijke B , Brown, Paul D. , Bulbeck, Helen , Chang, Susan M. , Coens, Corneel , Grant, Robin, Jalali, Rakesh , Koekkoek, Johan A F , Panda, Pankaj Kumar , Leach, Danielle, Mendoza, Tito R. , Nayak, Lakshmi , Oliver, Kathy , Reijneveld, Jaap C. , Taylor, Jennie , Wen, Patrick Y. , Taphoorn, Martin , Walbert, Tobias , Blakeley, Jaishri O , Bulbeck, Helen , Gilbert, Mark R , Grant, Robin , Jalali, Rakesh , Nayak, Lakshmi , Le Rhun, Emilie , Taylor, Jennie W , Weller, Michael , Mendoza, Tito , Koekkoek, Johan A F , Dirven, Linda , Armstrong, Terri S. , Bent, Martin J. van den , Chang, Susan Marina , Gilbert, Mark R. , Leeper, Heather , Rhun, Émilie Le , Rubinstein, Larry , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | April 28, 2025 | Volume: 27 | Issue: 9 | Pages: 2399-2414

10.1093/neuonc/noaf108 | PMID 40293144 Get It

Abstract Background Instruments to assess patient-reported outcomes (PRO) should generate high-quality evidence. Reliable PRO evidence is essential to policymakers, in conjunction with outcomes such as survival and radiological response, to understand the net clinical benefit of antitumor treatments. This study aimed to establish the content validity of 215 identified PRO measures used in patients with brain tumors. Methods A survey (n = 148 items) was developed reflecting aspects of the WHO International Classification of Functioning, Disability, and Health (ICF) framework. Patients with brain tumors, their proxies, and healthcare professionals (HCPs) were asked to rate each survey item on relevance. An item was considered a relevant issue if ≥25% of the patients or proxies or ≥50% of the HCPs considered that item to be an issue. Next, all items in the identified PRO measures were linked to ICF and relevant items in the survey, and the percentage of content coverage was calculated. Results In total, 114 patients, 71 proxies, and 65 HCPs from different countries completed the survey. Fifty-six of 148 (37.8%) items in the survey were considered relevant. The most important aspects mentioned by both patients and proxies were difficulty concentrating, difficulty remembering, multitasking, and handling stress. Depending on the definition, between 35% and 49% of PRO measures were considered to have sufficient content validity (≥80% coverage). Conclusion The content validity was insufficient in more than half of the identified PRO measures, particularly multidimensional measures. Future research should investigate whether different approaches to PRO assessment better meet the needs of all stakeholders.
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Bando, Hideaki , Takeda, Yuriko , Misumi, Toshihiro , Nishikawa, Tomomi, Wakabayashi, Masashi , Yamazaki, Kentaro , Oki, Eiji , Douillard, Jean‐Yves , Punt, Cornelis J. A. , Koopman, Miriam , Bokemeyer, Carsten , Lenz, Heinz‐Josef , Maehara, Yoshihiko , Gramont, Aimery de, Yoshino, Takayuki , Van Cutsem, Eric , Venook, Alan P , Lenz, Heinz-Josef , Maehara, Yoshihiko , André, Thierry , Shi, Qian , De Gramont, Aimery , Yoshino, Takayuki , Oki, Eiji , Bando, Hideaki , Cutsem, Eric Van , Venook, Alan P. , André, Thierry , Shi, Qian , Gramont, Aimery de

Mayo Clinic

JNCI Cancer Spectrum | April 26, 2025 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/jncics/pkaf042 | PMID 40280867 Get It

Abstract Background Early tumor shrinkage and depth of response have emerged as potential prognostic indicators in metastatic colorectal cancer (CRC). However, their associations with overall survival, progression-free survival (PFS), and postprogression survival in patients receiving anti–epidermal growth factor receptor (EGFR) antibodies or bevacizumab remain unclear. Methods We analyzed 3219 treatment-naive patients with RAS wild-type metastatic CRC from 8 randomized studies (CRYSTAL, OPUS, PRIME, CAIRO2, CALGB80405, WJOG4407G, ATOM, PARADIGM) in the Aid and Research in Digestive Cancerology database. Early tumor shrinkage was defined as a 20% or more reduction in tumor size at 8 ± 2 weeks, whereas depth of response was assessed by maximum tumor shrinkage at nadir. Cox regression models evaluated the associations of early tumor shrinkage and depth of response with overall survival, PFS, and postprogression survival, adjusting for confounders. A 2-sided test was conducted with a significance level of .05. Results Early tumor shrinkage and depth of response substantially stratified overall survival, PFS, and postprogression survival outcomes across all treatment groups. Early tumor shrinkage positivity was associated with improved overall survival, PFS, and postprogression survival in anti-EGFR and bevacizumab-based therapies, with a trend toward better outcomes in the anti-EGFR group. The depth of response analysis revealed optimal cutoff values of 0.55 for anti-EGFR–based therapy and 0.47 for bevacizumab-based therapy to achieve a median overall survival of approximately 32 months. Conclusions Early tumor shrinkage and depth of response serve as valuable prognostic markers in RAS wild-type metastatic CRC, particularly for patients treated with anti-EGFR antibodies. These findings highlight the potential role of early tumor shrinkage and depth of response in guiding treatment strategies and improving outcomes for patients with CRC.
68. The Use of Spino-plastic Surgery in Patients With Complex Spinal Reconstructive Needs: An Initial Cohort And Associated Outcomes
Reece, Edward M., Buchanan, D., Unadkat, Krishna , Vernik, Daniel M. , Jeger, Jonathan L. , Spronsen, Nicole R. Van, Meyer, Jenna H., Kalani, Maziyar A. , Unadkat, Krishna D , Jungbauer, Walter N , Buchanan, Dylon C., Jeger, Jonathan L , Spronsen, Nicole Van

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 46-47

10.1097/01.gox.0001112224.42767.e4 Get It

Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia
Liu, Xulin , Cortez, Kasey, Poos, Jackie M. , Illán‐Gala, Ignacio , Heuer, Hilary W. , Forsberg, Leah K. , Casaletto, Kaitlin B. , Memel, Molly , Barmada, Sami J. , Clark, David , Darby, Ryan, Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kantarci, Kejal, Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Masellis, Mario, Jiskoot, Lize C. , Laforce, Robert, Graff, Caroline , Galimberti, Daniela, Vandenberghe, Rik, Santana, Isabel, Xiong, Chengjie , Sorbi, Sandro , Otto, Markus , Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Synofzik, Matthis , Moreno, Fermín , Boxer, Adam L. , Rosen, Howie, Rohrer, Jonathan D., Kantarci, Kejal , Galimberti, Daniela , Bocchetta, Martina , Moreno, Fermín , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Pascual, Belen , Synofzik, Matthis , Xiong, Chengjie , Domoto-Reilly, Kimiko , Barmada, Sami , Otto, Markus , Illán-Gala, Ignacio , Galimberti, Daniela , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Boer, Sterre C.M. de , Appleby, Brian S. , Bozoki, Andrea C , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Irwin, David J. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Bayram, Ece , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Pasquier, Florence , Ber, Isabelle Le , Finger, Elizabeth C. , Rowe, James B. , Borroni, Barbara , Boeve, Bradley F. , Pijnenburg, Yolande A.L. , Rohrer, Jonathan D. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14608 | PMID 40277074 Get It

AbstractINTRODUCTIONHigher male prevalence in sporadic behavioral variant frontotemporal dementia (bvFTD) has been reported. We hypothesized differences in phenotypes between genetic and sporadic bvFTD females resulting in underdiagnosis of sporadic bvFTD females.METHODSWe included genetic and sporadic bvFTD patients from two multicenter cohorts. We compared behavioral and cognitive symptoms, and gray matter volumes, between genetic and sporadic cases in each sex.RESULTSFemales with sporadic bvFTD showed worse compulsive behavior (p = 0.026) and language impairments (p = 0.024) compared to females with genetic bvFTD (n = 152). Genetic bvFTD females had smaller gray matter volumes than sporadic bvFTD females, particularly in the parietal lobe.DISCUSSIONFemales with sporadic bvFTD exhibit a distinct clinical phenotype compared to females with genetic bvFTD. This difference may explain the discrepancy in prevalence between genetic and sporadic cases, as some females without genetic mutations may be misdiagnosed due to atypical bvFTD symptom presentation.Highlights Sex ratio is equal in genetic behavioral variant of frontotemporal dementia (bvFTD), whereas more males are present in sporadic bvFTD. Distinct neuropsychiatric phenotypes exist between sporadic and genetic bvFTD in females. Phenotype might explain the sex ratio difference between sporadic and genetic cases.
Isolation of Multiple Positive Cultures at Resection Arthroplasty is a Predictor of Failure Following Reimplantation
Tarabichi, Saad , Deckey, David G. , Verhey, Jens T. , Schuyver, Paul Van , Lin, Eugenia , Braithwaite, Collin , Wyles, Cody C. , Springer, Bryan D. , Van Schuyver, Paul R , Christopher, Zachary K. , Clarke, Henry D. , Spangehl, Mark J. , Wyles, Cody C , Braithwaite, Collin L , Bingham, Joshua S.

Mayo Clinic

Journal of Bone and Joint Surgery | April 24, 2025 | Volume: 107 | Issue: 12 | Pages: 1316-1323

10.2106/jbjs.24.01212 | PMID 40273213 Get It

Background: Although it is well established that the type of organism can be a risk factor for failure in patients with periprosthetic joint infection (PJI), no study to date has examined the impact of the number of positive cultures on treatment outcomes in patients undergoing 2-stage exchange. The purpose of this multicenter study was to determine the prognostic utility of multiple positive cultures at resection as a predictor of failure following reimplantation. Methods: This retrospective multicenter study identified 437 patients with chronic knee PJI who had undergone 2-stage exchange arthroplasty with a minimum of 1 year of follow-up following reimplantation. PJI was defined with use of the 2013 Musculoskeletal Infection Society (MSIS) criteria. Patients with culture-negative PJI were excluded (n = 138). Treatment failure was defined as either any reoperation for infection or PJI-related mortality. Multivariable regression controlling for risk factors for failure after a 2-stage arthroplasty was performed to determine whether ≥2 positive intraoperative cultures at resection can predict outcomes following reimplantation when compared with a single positive culture. Results: Two hundred and ninety-nine patients were included. At a mean follow-up of 6.2 ± 2.6 years, 48 patients (16.1%) experienced failure. Patients who had a failure were more likely to have had a longer interstage interval (p = 0.038) and were also more likely to have had ≥2 positive cultures at the time of resection arthroplasty (95.8% versus 75.3%; p = 0.001). On regression analysis, ≥2 positive cultures at resection was the only variable that was identified as a risk factor for failure following reimplantation in both the univariate (odds ratio [OR], 7.55 [95% CI, 2.24 to 47.0]; p = 0.006) and multivariable models (OR, 8.12 [95% CI, 2.31 to 51.9]; p = 0.005). Conclusions: This is the first study to examine the impact of the number of positive cultures on outcomes in patients with PJI. We found that the presence of ≥2 positive cultures at resection was an indicator of a poor prognosis and resulted in a greater than eightfold increase in the risk of treatment failure in patients undergoing a 2-stage exchange. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy for prevention of recurrent Clostridioides difficile infectio
Khanna, Sahil , Yoho, David, Handel, Daniel Van, Clark, Brian J., Awad, Tahany , Guthmueller, Beth, Armandi, Daniel, Knapple, W , Safdar, Nasia , Baggott, Brian, Simon, Karen, Knapple, Whitfield , Feuerstadt, Paul , Feuerstadt, Paul

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 23, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251339697 | PMID 40321366 Get It

Background: Recurrent Clostridioides difficile infection (rCDI) occurs in up to 35% of patients with CDI, and further recurrence is common. Fecal microbiota, live-jslm (RBL) is safe and effective for preventing rCDI in adults following antibiotic treatment for rCDI when administered rectally. There is clinical interest in alternative routes of administration. Objectives: CDI-SCOPE assessed the safety and clinical effectiveness of RBL when administered via colonoscopy to adults with rCDI. Design: Single-arm, exploratory phase IIIb trial conducted at 12 sites in the United States. Methods: Eligible adults with rCDI received one administration of RBL consisting of one 150-mL dose of RBL, delivered via colonoscopy to the right side of the colon. The primary endpoint assessed RBL-related treatment-emergent adverse events (TEAEs) within 8 weeks of RBL administration or until confirmed treatment failure. Secondary endpoints included treatment success (absence of CDI recurrence for 8 weeks following RBL administration), physician experience administering RBL via colonoscopy, and physician perception of participant benefit. Results: Of 54 participants screened, 41 were enrolled and received RBL via colonoscopy; 39 participants completed the 8-week visit. Five TEAEs in four participants (9.8%) were assessed as related to RBL, all of which were gastrointestinal and mild in severity. Overall, 18 participants (43.9%) experienced 33 TEAEs within 8 weeks, most of which were of mild (25/33; 75.8%) or moderate (5/33; 15.2%) severity. No TEAEs led to intensive care unit admission or death. Overall, 39 participants (95.1%) experienced treatment success; 2 participants (4.9%) withdrew consent and had an indeterminate outcome. Among physicians, 90.2% of investigators indicated a “positive” or “very positive” experience administering RBL by colonoscopy. All physicians assessed participant benefit as “much” or “very much” improved. Conclusion: This single-arm study suggests RBL administered via colonoscopy is practical, safe, and effective for preventing CDI recurrence following antibiotic treatment in adults. Trial registration: ClinicalTrials.gov: NCT05831189.